LINEAGE CELL THERAPEUTICS LCTX 深 沪
已收盘 05-08 16:00:00 美东时间
1.37
0.000
0.00%
华盛通- 最 高1.40
- 今 开1.38
- 成交量 116.65万股
- 最 低 1.35
- 昨 收 1.37
- 总市值 3.42亿
- 52周最高 2.09
- 市盈率 静 --
- 换手率 0.47%
- 52周最低 0.451
- 委 比 39.82%
- 总股本 2.49亿
- 历史最高 3.132
- 量 比 0.77
- 振 幅 3.65%
- 历史最低 0.3651
- 每 手 1
- 风险率 0.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines
Issued on behalf of Avaí Bio, Inc. USANewsGroup.com News Commentary VANCOUVER, BC, April 6, 2026 /PRNewswire/ -- The global cell therapy manufacturing market is on track to nearly double, fr...
04-07 01:10
Service Properties Trust, ConocoPhillips And Other Big Stocks Moving Lower In Monday's Pre-Market Session
US stock futures up, Nasdaq 100 gains 100 pts. Service Properties Trust (SVC) drops 4% in pre-market trading. Other decliners: MGRT, UP, CDZI, LCTX, KEP, AUTL, EOG, ANGX, COP.
04-06 20:03
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.
03-24 23:19
Lineage Cell Therapeutics Expands Cell Transplant Pipeline With COR1
New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing ExpertiseFuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population with a Predicted
03-24 20:07
Lineage Therap Expands ATM Equity Offering Capacity
Lineage Therap ( ($LCTX) ) has provided an announcement. On March 11, 2026, Lin...
03-11 21:51
美股大行评级 | 潜在涨幅183%！迈威尔科技获10家机构上调目标价最高至164美元；伯灵顿百货、好市多、Ciena、Samsara等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持BridgeBio Oncology"买入"评级，目标价从27美元升至29美元；韦德布什：维持WAVE Life Sciences"跑赢大市"评级，目标价从33美元升至35美元
03-09 11:47
Lineage Cell Therapeutics Extends Runway Amid R&D Surge
Lineage Cell Therapeutics, Inc. (($LCTX)) has held its Q4 earnings call. Read o...
03-08 08:17
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Raises Price Target to $3
D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and raises the price target from $2 to $3.
03-07 02:42
Lineage Cell Therapeutics Q4 Earnings Summary & Key Takeaways
Lineage Cell Therapeutics (AMEX:LCTX) reported its Q4 earnings results on Thurs...
03-06 05:04
